Currently the healthcare industry is facing a huge opportunity, however taking advantage of this opportunity requires navigating a significant challenge. The leading pharmaceutical companies are starting to shift their focus from the traditional 'one-size-fits-all' approach to medications to a more tailored approach. The era of personalised medicine is here. These developments come hand in hand with the fact that payers and health technology assessors are increasingly looking for more value for money in health spending. Several organisations maintain that they are willing to invest in drugs that offer significantly improved levels of patient safety and efficacy, if somehow clinical outcomes data can provide compelling evidence of real added value. More and more HTA agencies are realising the potentially strong benefits of reimbursing drugs that are targeted towards a genetically defined patient population. The event ...
Personalised Medicine: Overcoming Regulatory and Commercial Challenges is a 1/2 day web-forum focused deeply on market and patient access for personalised medicine.